4.6 Article

Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists

Journal

PLOS ONE
Volume 7, Issue 11, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0049910

Keywords

-

Funding

  1. DFG Emmy-Noether Fellowship [KO 4095/1-1]
  2. National Institutes of Health/National Institute of General Medical Sciences [R01 GM083960]
  3. National Institute of Diabetes and Digestive and Kidney Diseases Intramural Research Program [1ZIADK031117-24]

Ask authors/readers for more resources

G protein-coupled receptors (GPCRs) are attractive targets for pharmaceutical research. With the recent determination of several GPCR X-ray structures, the applicability of structure-based computational methods for ligand identification, such as docking, has increased. Yet, as only about 1% of GPCRs have a known structure, receptor homology modeling remains necessary. In order to investigate the usability of homology models and the inherent selectivity of a particular model in relation to close homologs, we constructed multiple homology models for the A(1) adenosine receptor (A(1)AR) and docked similar to 2.2 M lead-like compounds. High-ranking molecules were tested on the A(1)AR as well as the close homologs A(2A)AR and A(3)AR. While the screen yielded numerous potent and novel ligands (hit rate 21% and highest affinity of 400 nM), it delivered few selective compounds. Moreover, most compounds appeared in the top ranks of only one model. These findings have implications for future screens.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Fluorescent A2A and A3 adenosine receptor antagonists as flow cytometry probes

Kiran S. Toti, Ryan G. Campbell, Hobin Lee, Veronica Salmaso, R. Rama Suresh, Zhan-Guo Gao, Kenneth A. Jacobson

Summary: Adenosine receptor (AR) ligands are being developed for the treatment of metabolic, cardiovascular, neurological, and inflammatory diseases and cancer. Fluorescent antagonist ligands were synthesized and screened for their affinities and selectivity towards different AR subtypes, showing potential as live cell or in vivo imaging tools and/or therapies.

PURINERGIC SIGNALLING (2023)

Book Review Chemistry, Medicinal

The Ups and Downs in Drug Design: Adventures in Medicinal Chemistry

Kenneth A. Jacobson

CHEMMEDCHEM (2023)

Article Chemistry, Medicinal

Pose, duplicate, then elaborate: Steps towards increased affinity for inhibitors targeting the specificity surface of the Pim-1 kinase

Lukas Heyder, Phil M. M. Hochban, Corey Taylor, Florent Chevillard, Christof Siefker, Christian Iking, Hannes Borchardt, Achim Aigner, Gerhard Klebe, Andreas Heine, Peter Kolb, Wibke E. Diederich

Summary: In this study, fragment-sized hits binding to Pim-1 kinase were optimized using a combination of computational, synthetic, and crystallographic expertise. The resulting potent ligands target rarely-targeted regions of Pim-1 kinase with affinities in the nanomolar range. The combination of computational and experimental approaches successfully developed a novel molecular scaffold for inhibition of Pim-1 kinase, targeting specific surface regions that have been less frequently investigated.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Neurosciences

New paradigms in purinergic receptor ligand discovery

Kenneth A. Jacobson, Balaram Pradhan, Zhiwei Wen, Asmita Pramanik

Summary: The discovery and clinical implementation of adenosine, P2Y and P2X receptor modulators have advanced significantly in the past 50 years. Although previous clinical trials of selective ligands have not been successful, there is now a renewed focus on new disease conditions and the development of more selective compounds, as well as the elucidation of new receptor and enzyme structures.

NEUROPHARMACOLOGY (2023)

Article Chemistry, Medicinal

Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs

Jung-Eun Park, Hobin Lee, Paola Oliva, Klara Kirsch, Bora Kim, Jong Il Ahn, Celeste N. Alverez, Snehal Gaikwad, Kristopher W. Krausz, Robert O'Connor, Ganesha Rai, Anton Simeonov, Beverly A. Mock, Frank J. Gonzalez, Kyung S. Lee, Kenneth A. Jacobson

Summary: Polo-like kinase 1 (Plk1) is an attractive target for anticancer drug discovery due to its widely upregulated activity in various human cancers. In addition to the kinase domain, the C-terminal noncatalytic polo-box domain (PBD) has emerged as an alternative target for developing inhibitors. Triazoloquinazolinone-derived inhibitors effectively block Plk1 with improved affinity and drug-like properties. Further derivatization is needed to improve the stability of these inhibitors for the development of therapeutics against Plk1-addicted cancers.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2023)

Article Biochemistry & Molecular Biology

Synthesis and biological evaluation of carboxamide and quinoline derivatives as P2X7R antagonists

Qasim Shah, Zahid Hussain, Bilal Ahmad Khan, Kenneth A. Jacobson, Jamshed Iqbal

Summary: The study investigates the potency of P2X7 receptor antagonists and their relationship with cancer, revealing five compounds with strong selective inhibitory effects. These compounds exhibit varying cell viability and induction of apoptosis in transfected and non-transfected cell lines.

BIOORGANIC CHEMISTRY (2023)

Article Chemistry, Medicinal

Structure activity relationships of 5-HT2B and 5-HT2C serotonin receptor antagonists: N-6, C2 and 5 '-Modified (N)-methanocarba-adenosine derivatives

Dilip K. Tosh, Maggie M. Calkins, Marko S. Ivancich, Hailey A. Bock, Ryan G. Campbell, Sarah A. Lewicki, Eric Chen, Zhan-Guo Gao, John D. Mccorvy, Kenneth A. Jacobson

Summary: Derivatives of (N)-Methanocarba adenosine were modified to target 5-HT2B serotonin receptors as antagonists, showing affinity enhancement with the bicyclic ring system. Compound 43 (MRS7925) exhibited potential for anti-fibrotic therapy due to its affinity and moderate 5-HT2BR binding selectivity. The compounds also demonstrated dual action as 5-HT2B antagonists and A(1)AR agonists.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Pharmacology & Pharmacy

Anti-inflammatory potency of novel ecto-5'-nucleotidase/CD73 inhibitors in astrocyte culture model of neuroinflammation

Katarina Mihajlovic, Marija Adzic Bukvic, Milorad Dragic, Mirko Scortichini, Kenneth A. Jacobson, Nadezda Nedeljkovic

Summary: In this in vitro study, three novel cytosine-derived alpha,beta-methylene diphosphonates (MRS4598, MRS4552, and MRS4602) were tested for their potency in inhibiting CD73 activity and attenuating reactive astrocyte phenotype. The results showed that all compounds exhibited concentration-dependent inhibition of CD73 activity with high inhibitory potency and binding capacity. Among them, MRS4598 was the most effective in inhibiting CD73 activity and inducing reactive astrocyte phenotype inhibition, making it a promising tool for the treatment of neurodegeneration and neuroinflammation.

EUROPEAN JOURNAL OF PHARMACOLOGY (2023)

Article Chemistry, Medicinal

Alicyclic Ring Size Variation of 4-Phenyl-2-naphthoic Acid Derivatives as P2Y14 Receptor Antagonists

Zhiwei Wen, Asmita Pramanik, Sarah A. Lewicki, Young-Hwan Jung, Zhan-Guo Gao, John C. R. Randle, Chunxia Cronin, Zhoumou Chen, Luigino A. Giancotti, Gregory S. Whitehead, Bruce T. Liang, Sylvie Breton, Daniela Salvemini, Donald N. Cook, Kenneth A. Jacobson

Summary: P2Y(14) receptor is activated by extracellular UDP-glucose, promoting inflammation in various tissues. Selective P2Y(14)R antagonists could be useful for inflammatory and metabolic diseases.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

Development of Fluorescent AF64394 Analogues Enables Real-Time Binding Studies for the Orphan Class A GPCR GPR3

Merlin Bresinsky, Aida Shahraki, Peter Kolb, Steffen Pockes, Hannes Schihada

Summary: In this study, a signaling pathway-independent readout of compound-GPR3 interaction was developed, providing new cues for the pharmacological manipulation of GPR3 activity. This has significant implications for the future development of drugs targeting these pharmacologically attractive oGPCRs.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Chemistry, Multidisciplinary

Stereocontrolled access to thioisosteres of nucleoside di- and triphosphates

Hai-Jun Zhang, Michal Ociepa, Molhm Nassir, Bin Zheng, Sarah A. Lewicki, Veronica Salmaso, Helay Baburi, Jessica Nagel, Salahuddin Mirza, Haneen Al-Hroub, Beatriz Bueschbell, Olga Perzanowska, Ziqin Lin, Michael A. Schmidt, Martin D. Eastgate, Kenneth A. Jacobson, Christa E. Mueller, Joanna Kowalska, Jacek Jemielity, Phil S. Baran

Summary: Nucleoside diphosphates and triphosphates have a profound impact on biochemistry, but their usage as tools or medicinal leads for nucleotide-dependent enzymes and receptors is hindered by their rapid metabolism in the body. This study demonstrates the development of a modular, reagent-based platform that allows the stereocontrolled and scalable synthesis of pure stereoisomers of nucleoside thioisosteres, which can have significant effects on ligand-receptor interactions.

NATURE CHEMISTRY (2023)

Article Chemistry, Medicinal

Assay-Dependent Inverse Agonism at the A(3) Adenosine Receptor: When Neutral Is Not Neutral

Eline Pottie, R. Rama Suresh, Kenneth A. Jacobson, Christophe P. Stove

Summary: This study aimed to explore inverse agonism at A(3)AR using two engineered cell lines and NanoBiT technology. The previously established inverse agonist PSB-10 showed inverse agonism in one assay but not in another. Further experiments confirmed the specificity and reversibility of this observation. Evaluation of presumed neutral antagonists revealed their concentration-dependent inverse agonism in the A(3)AR-βarr2 recruitment assay.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2023)

Article Chemistry, Medicinal

First Potent Macrocyclic A(3) Adenosine Receptor Agonists Reveal G-Protein and & beta;-Arrestin2 Signaling Preferences

Dilip K. Tosh, Courtney L. Fisher, Veronica Salmaso, Tina C. Wan, Ryan G. Campbell, Eric Chen, Zhan-Guo Gao, John A. Auchampach, Kenneth A. Jacobson

Summary: (N)-Methanocarba adenosine derivatives were modified to form macrocyclic A(3) adenosine receptor agonists. These macrocycles retained affinity and had a spatially proximal orientation on the receptor. C2-Arylethynyl-linked macrocycle 19 showed higher selectivity for A(3) adenosine receptor compared to 2-ether-linked macrocycle 12.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2023)

Article Biochemistry & Molecular Biology

Shedding Light on the D1-Like Receptors: A Fluorescence-Based Toolbox for Visualization of the D1 and D5 Receptors

Niklas Rosier, Denise Moennich, Martin Nagl, Hannes Schihada, Alexei Sirbu, Nergis Konar, Irene Reyes-Resina, Gemma Navarro, Rafael Franco, Peter Kolb, Paolo Annibale, Steffen Pockes

Summary: Dopamine D-1-like receptors are the most abundant type of dopamine receptors in the central nervous system. The synthesis of new fluorescent ligands derived from D1R antagonist SCH-23390 was described, which can be used as tools for the visualization of D-1-like receptors. The high-affinity ligand UR-NR435 (25) showed excellent selectivity towards D-1-like receptors and proved to be a neutral antagonist in binding studies. This fluorescent ligand is a useful tool for studying native D-1 receptors in various experimental setups.

CHEMBIOCHEM (2023)

Article Biochemistry & Molecular Biology

Fluorescent Tools for the Imaging of Dopamine D2-Like Receptors

Martin Nagl, Denise Moennich, Niklas Rosier, Hannes Schihada, Alexei Sirbu, Nergis Konar, Irene Reyes-Resina, Gemma Navarro, Rafael Franco, Peter Kolb, Paolo Annibale, Steffen Pockes

Summary: This study describes the synthesis of a set of new fluorescent ligands for visualization of dopamine D-2-like receptors. The ligand UR-MN212 (20) showed high affinity for D-2-like receptors and moderate selectivity towards D-1-like receptors. It displayed rapid association with D2longR and can be used for fluorescence microscopy studies. The ligand's binding affinity was determined in a single-digit nanomolar range, consistent with radioligand binding data.

CHEMBIOCHEM (2023)

No Data Available